HOWL WEREWOLF THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, WEREWOLF THERAPEUTICS INC reported revenue of n/a, net income of $3.67M and diluted EPS of $0.08; for the fiscal year ended December 2025 revenue was n/a.
HOWL annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$60.7M, net income −$60.8M (margin n/a), EPS −$1.33
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$73.6M, net income −$70.5M (margin n/a), EPS −$1.63
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$40.5M, net income −$37.4M (margin n/a), EPS −$1.05
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$56.1M, net income −$53.8M (margin n/a), EPS −$1.86
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$50.1M, net income −$50.0M (margin n/a), EPS −$10.94
HOWL quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income $3.67M, EPS $0.08
- Quarter ended Mar 31, 2026: revenue n/a, net income −$13.5M, EPS −$0.28
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$8.38M, EPS −$0.17
- Quarter ended Sep 30, 2025: revenue n/a, net income −$16.4M, EPS −$0.36
- Quarter ended Jun 30, 2025: revenue n/a, net income −$18.0M, EPS −$0.40
- Quarter ended Mar 31, 2025: revenue n/a, net income −$18.1M, EPS −$0.40
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$20.4M, EPS −$0.43
- Quarter ended Sep 30, 2024: revenue n/a, net income −$16.7M, EPS −$0.38
- Quarter ended Jun 30, 2024: revenue n/a, net income −$17.2M, EPS −$0.43
- Quarter ended Mar 31, 2024: revenue n/a, net income −$16.2M, EPS −$0.39
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$12.0M, EPS −$0.34
- Quarter ended Sep 30, 2023: revenue n/a, net income −$8.29M, EPS −$0.23
- Quarter ended Jun 30, 2023: revenue n/a, net income −$5.10M, EPS −$0.14
- Quarter ended Mar 31, 2023: revenue n/a, net income −$12.0M, EPS −$0.34
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$11.9M, EPS −$0.37
- Quarter ended Sep 30, 2022: revenue n/a, net income −$11.9M, EPS −$0.40
- Quarter ended Jun 30, 2022: revenue n/a, net income −$14.6M, EPS −$0.53
- Quarter ended Mar 31, 2022: revenue n/a, net income −$15.3M, EPS −$0.56
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$17.9M, EPS $76.75
- Quarter ended Sep 30, 2021: revenue n/a, net income −$13.8M, EPS −$0.51
HOWL cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$60.3M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$56.2M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$32.6M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$40.6M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$42.9M, share buybacks n/a
HOWL balance sheet
- Jun 30, 2026: cash $22.0M, total assets $24.2M, total liabilities $7.86M, shareholders' equity $16.3M
- Mar 31, 2026: cash $46.5M, total assets $58.0M, total liabilities $45.8M, shareholders' equity $12.2M
- Dec 31, 2025: cash $57.1M, total assets $69.4M, total liabilities $44.6M, shareholders' equity $24.8M
- Sep 30, 2025: cash $65.7M, total assets $79.6M, total liabilities $50.0M, shareholders' equity $29.6M
- Jun 30, 2025: cash $77.6M, total assets $92.6M, total liabilities $51.1M, shareholders' equity $41.5M
- Mar 31, 2025: cash $92.0M, total assets $107M, total liabilities $49.9M, shareholders' equity $57.3M
- Dec 31, 2024: cash $111M, total assets $127M, total liabilities $53.5M, shareholders' equity $73.4M
- Sep 30, 2024: cash $123M, total assets $140M, total liabilities $50.7M, shareholders' equity $89.4M
Is HOWL profitable?
No. WEREWOLF THERAPEUTICS INC lost $34.6M over the last four quarters.
What is HOWL's EPS?
Diluted earnings per share over the last four quarters were −$0.73; $0.08 in the latest quarter.